We'll get some Hiv news before long
This is no different than a traditional note holder. When the notes roll over on themselves the note holder always wants & gets 9.99 percent more notes.
There is no genius being in Switzerland & operating via notes in an off shore trust. Smarter, yes. Tax benefits, assuming ya don't get your hand caught in the cookie jar & I don't need to mind you about that one.
I'm not a financier nor a bio scientist either but experienced & think
This filing isn't bad, the last one like it wasn't. Heck, it got them roughly 4 years
but ya from the last Q
As of September 30, 2019, the Company was engaged in the pre-clinical testing of some of its vaccine candidates and a commercially viable product is not expected for several more years. The Company is working on several research projects with commercial partners for immunotherapy in the fields of allergy and oncology. The allergy project is in collaboration with Anergis SA, for which the Company prepared virosome based vaccines which include Anergis peptides for treating birch pollen allergy. These formulations were tested in preclinical studies and compared to the Anergis earlier clinical trial formulations. The success criteria were met in December 2018 and Anergis has now a time limited exclusive option to enter into a License and Collaboration Agreement (“LCA”) with Mymetics for the use of virosomes in the field of allergies that will require Anergis to raise funds from third parties to pay Mymetics the license fee under the terms of the LCA and the clinical development, and there is no certainty that Anergis will be able to do so. At the end of 2018 the Company finished the grant funded project in the field of HIV from the EU Horizon 2020 and Switzerland SERI which focused on developing thermostable and cold chain independent virosome based vaccines (MACIVIVA project). Management believes that the Company’s research and development activities will result in valuable intellectual property that can generate significant revenues in the future through licensing. Vaccines are one of the fastest growing markets in the pharmaceutical industry.
I just personally think 2020 will be better & 2021 better than that just based on what Mr K has in the filings & what Stallergenes brings to the timeline fits very well.
Hanging w/ ya
